CTNNB1 S37F is a gain-of-function mutation that could lead to aberrant activation of the WNT/β-catenin signaling, which is enriched in non-T cell inflamed tumors[20,21] and has been linked to lack of benefit of immunotherapy in NSCLC.[22] Whereas, ARID2 E1056X is a loss-of-function mutation. The gene discussed is ARID2; the disease is non-small cell lung carcinoma.